The link between MGMT expression and outcomes in H3 G34-mutant diffuse hemispheric glioma persists after accounting for pre-analytic and technical factors

1

The analysis included 110 H3 G34-mutant diffuse hemispheric gliomas centrally sequenced at St. Jude, excluding four older-platform specimens omitted from the original analysis.
2

After normalization and batch correction, release year no longer distinguished samples, and excluding low-complexity outliers did not change subsequent results.
3

Adjusting for collection year, preservation method, data release year, or tumor content did not eliminate the association between MGMT expression and outcomes in 25 patients.
4

Per doubling of MGMT expression, adjusted hazard ratios were 1.64 for progression-free survival and 3.00 for overall survival.
5

MGMT expression remained associated with methylation at three gene-body or intronic CpG sites after adjustment, while the authors noted that larger prospective validation is needed before therapy guid

1